Author + information
- Published online February 14, 2018.
- Theresa Reiter, MD,
- Malte Kircher, MD,
- Andreas Schirbel, PhD,
- Rudolf A. Werner, MD,
- Saskia Kropf, MEng,
- Georg Ertl, MD,
- Andreas K. Buck, MD,
- Hans-Jürgen Wester, PhD,
- Wolfgang R. Bauer, PhD, MD and
- Constantin Lapa, MD∗ ()
- ↵∗Department of Nuclear Medicine, University Hospital Würzburg, Oberdürrbacher Strasse 6, 97080 Würzburg, Germany
C-X-C motif chemokine receptor 4 (CXCR4) and its ligand stromal cell-derived factor-1α have been shown to be involved in the orchestration of post-infarct inflammation and its resolution in patients with acute myocardial infarction (AMI) (1). Recently, pilot visualization of CXCR4-expression using a radiolabeled PET ligand ([68Ga]Pentixafor) could be demonstrated in patients after AMI (2,3). The aim of this study was to further investigate CXCR4 expression after myocardial ischemia in comparison to cardiac magnetic resonance (CMR).
From January 2015 to June 2016, 22 patients (17 men and 5 women, mean age 61 ± 11 years) with (sub) acute myocardial infarction underwent imaging with [68Ga]Pentixafor-positron emission tomography (PET)/computed tomography (CT) and CMR (21 patients, 1 patient excluded because of adipositas permagna) within 2 to 13 days after onset of symptoms (median delay between PET and CMR: 1 day). Thirteen patients returned for follow-up CMR (1 to 14 months; median: 4 months). A total of 75 ± 15 min after injection of 116 ± 29 MBq of [68Ga]Pentixafor, PET/CT was performed (2). Images were first inspected visually. For semi-quantitative analysis, the axial PET image slice with maximum cardiac uptake was selected. A standardized 10-mm circular region was placed over the area with the peak activity to derive maximum and peak standardized uptake values. For signal-to-background ratios, peak standardized uptake values were also derived in normal reference regions by a second region of interest (diameter: 10 mm) in a remote region of the left ventricular wall without late-gadolinium-enhancement (LGE) in the corresponding CMR data. For multi-organ analysis of [68Ga]Pentixafor uptake, mean standardized uptake values were also derived for bone marrow (thoracic vertebrae) and spleen. These PET parameters were then correlated with clinical (creatine kinase [CK], troponin T, leukocyte, and C-reactive protein levels) as well as with CMR parameters.
CMR was performed on a 1.5-T (n = 7) (Achieva 1.5-T, Philips Healthcare, Best, the Netherlands) and 3.0-T (n = 15) (Achieva DS 3.0-T, Philips Healthcare) scanner using dedicated protocols (2). In analogy to PET, LGE and T2-weighted images were analyzed for necrosis/Scar and edema, respectively (17-segment model). Concordant signal enhancement in both LGE and T2-weighted sequences was considered as CMR-positive for acute cardiac damage. LGE positivity associated with T2 negativity was rated as consistent with fibrotic changes.
Statistical analyses were performed using PASW Statistics software version 22.0 (SPSS, Inc., Chicago, Illinois). Quantitative values were expressed as mean ± SD or median and range as appropriate. Comparisons of related metric measurements were performed using the Wilcoxon-signed rank test. The chi-square or Fisher exact test was conducted for comparison of frequency data between independent subgroups. For bivariate correlation analyses, Pearson correlation coefficients were calculated. All statistical tests were performed 2-sided and a p value <0.05 was considered to indicate statistical significance. No correction was applied for p values to adjust for multiple tests.
On visual inspection, [68Ga]Pentixafor-PET was positive in 17 of 22 patients with AMI. On a segment basis, 65 of 306 segments were rated positive, concordant to CMR. Infarct-to-remote ratios were 2.2 ± 0.4 and infarct-to-left cavity ratios were 1.4 ± 0.1. CXCR4 expression could be observed up to 13 days after AMI and was negatively correlated with time after onset of symptoms (r = −0.73; p < 0.01). CXCR4 expression was not related to myocardial damage as assessed by initial troponin T or CK levels (all p > 0.40; all r > −0.24 and <0).
Regarding the systemic inflammatory response, CXCR4 expression in the bone marrow correlated with serum leukocyte levels (r = 0.64; p < 0.01). Splenic tracer uptake showed a negative correlation with organ size (r = −0.51; p = 0.03), CK levels (r = −0.62; p < 0.01) and with necrotic tissue volume (r = −0.67; p < 0.01). [68Ga]Pentixafor uptake and serum C-reactive protein levels showed no significant correlation (p = NS).
CXCR4 expression in the infarct area showed a negative correlation to scar volume at follow-up (normalized to body surface area, r = −0.64; p = 0.03) (Figure 1). [68Ga]Pentixafor uptake in the bone marrow correlated with better healing of the initial ischemic volume (r = −0.70; p < 0.01). Spleen standardized uptake values were negatively related with necrosis volume (r = −0.70; p < 0.01) and showed a positive correlation with ejection fraction at follow-up (r = 0.75; p < 0.01) and the change of ejection fraction (r = 0.72; p < 0.01) (Figure 1) when compared with baseline.
The current report of in vivo imaging of CXCR4 in the human heart demonstrates the feasibility of noninvasive chemokine receptor imaging up to 2 weeks after AMI. [68Ga]Pentixafor uptake in the infarcted myocardium strongly correlated with the time point of imaging with a linear decline up to day 13 after myocardial ischemia. Our findings, in parallel to the literature (3), suggest that infiltrating inflammatory cells can be assumed the major cellular source of the PET signal, potentially triggering a beneficial immune response (also evidenced by CXCR4 activation in bone marrow and spleen) that results in myocardial healing. Correspondingly, CXCR4 expression in the infarcted area also correlated with smaller scar volumes at follow-up.
This study has various limitations. First, a relatively small number of patients could be analyzed. Time points of PET and CMR imaging varied. No longitudinal CXCR4 imaging of the individual patients could be obtained. Molecular inflammatory endpoints including CXCR4/CXCL12 levels in the periphery were not assessed, and comparisons to imaging endpoints could not be performed. Histological proof of the cellular origin of the PET signal cannot be provided. Because CXCR4 expression was detected up to 2 weeks after the acute event, it cannot be excluded that at least a small fraction of the signal may stem from resident cells including cardiomyocytes, fibroblasts, endothelial cells or progenitor cells that were recruited to the damaged tissue (4,5).
In conclusion, this study suggests that CXCR4 expression after AMI as assessed by [68Ga]Pentixafor-PET is capable of revealing the myocardial healing potential. The investigation of underlying (patho)physiological mechanisms is a subject for further studies.
Please note: Dr. Wester is founder and shareholder, of Scintomics. Ms. Kropf is CEO of Scintomics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Reiter and Kircher contributed equally to this work and are joint first authors. Drs. Bauer and Lapa contributed equally to this work and are joint senior authors.
- 2018 American College of Cardiology Foundation
- Lapa C.,
- Reiter T.,
- Werner R.A.,
- et al.
- Thackeray J.T.,
- Derlin T.,
- Haghikia A.,
- et al.
- Hu X.,
- Dai S.,
- Wu W.J.,
- et al.
- Saxena A.,
- Fish J.E.,
- White M.D.,
- et al.